Telomere length and oxidative stress in small cell lung cancer patients changes through chemotherapy cycles compared to healthy controls
Biochemia medica · 2025
DOI: 10.11613/bm.2025.020705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemia medica, 2025. Verfasst von Azra Guzonjić und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia. Hauptthemen laut MEDLINE: Oxidative Stress, Lung Neoplasms, Small Cell Lung Carcinoma, Telomere. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Small cell lung cancer (SCLC) is an aggressive malignant disease with poor survival outcomes. The aim of this study was to investigate leukocyte telomere length (LTL) and redox status parameters during chemotherapy and evaluate their prognostic potential based on the hypothesis that shorter LTL and oxidative stress burden correlate with poorer survival. Materials and methods: This longitudinal study included 60 SCLC patients and 73 healthy controls. Leukocyte telomere length was measured by quantitative PCR (qPCR) method, while redox status parameters (MDA - malondialdehyde, IMA - ischemia-modified albumin, PON1 - paraoxonase 1, redox index) were determined by spectrophotometric methods before, after two and after four cycles of chemotherapy.
Results
All measured parameters showed significant differences between patients and controls, except the oxy-score (P < 0.001). Significant differences in IMA, PON1 and redox index were observed between SCLC patient groups at different time points (P < 0.001). Significant differences in IMA and PON1 were observed between SCLC survival groups, with higher values found in survivors after two chemotherapy cycles (P < 0.001). Redox index was the highest in the pre-chemo group (P = 0.019). Among patients who died, PON1 activity differed significantly between those who died within 2 months and after 4 months (P = 0.028). Kaplan-Meier analysis showed that LTL and PON1 were significant predictors of survival, with values below the 25th percentile associated with a higher risk of death.
Conclusions
Leukocyte telomere length and PON1 are potential prognostic biomarkers for SCLC survival, suggesting their potential use in non-invasive biomarker panels for improved patient stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
- Internal Medicine Clinic "Akta Medica", Belgrade, Serbia.
- Merck Sharp & Dohme d.o.o., Medical Affairs, Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Clinic for Pulmonology, University Clinical Center of Serbia, Belgrade, Serbia.
- Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
Zitieren
APA
Guzonjić, A., Jovanović, D., Simić, I., Ćeriman Krstić, V., Samardzić, N., Ostanek, B., Marc, J., Sopić, M., & Kotur Stevuljević, J. (2025). Telomere length and oxidative stress in small cell lung cancer patients changes through chemotherapy cycles compared to healthy controls. Biochemia medica. https://doi.org/10.11613/bm.2025.020705
Vancouver
Guzonjić A, Jovanović D, Simić I, Ćeriman Krstić V, Samardzić N, Ostanek B, et al. Telomere length and oxidative stress in small cell lung cancer patients changes through chemotherapy cycles compared to healthy controls. Biochemia medica. 2025. doi:10.11613/bm.2025.020705
BibTeX
@article{Guzonji2025,
author = {Guzonjić, Azra and Jovanović, Dragana and Simić, Ivana and Ćeriman Krstić, Vesna and Samardzić, Natalija and Ostanek, Barbara and Marc, Janja and Sopić, Miron and Kotur Stevuljević, Jelena},
title = {Telomere length and oxidative stress in small cell lung cancer patients changes through chemotherapy cycles compared to healthy controls},
journal = {Biochemia medica},
year = {2025},
doi = {10.11613/bm.2025.020705}
}
EUVIMED